Press Releases

Date Title and Summary Additional Formats
Toggle Summary Data Support the Potential Benefit of a Novel Ex Vivo Cell Modulation Approach to Improving Engraftment in Patients Undergoing Umbilical Cord Blood Transplantation Read All » View HTML
Toggle Summary U.S. Patent Covers Key Compositions Used in the Generation of Human Induced Pluripotent Stem Cells Read All » View HTML
Toggle Summary Secures U.S. Patent to Novel Small Molecule Modulator of Pluripotent Stem Cells Read All » View HTML
Toggle Summary Joins Strategic Investor Syndicate of Fate that Includes Four Pharmaceutical Companies Read All » View HTML
Toggle Summary Encouraging Phase 1b Clinical Data Presented at 2011 BMT Tandem Meetings Read All » View HTML
Toggle Summary Fate Therapeutics announces encouraging clinical results and change in management San Diego, CA – February 21, 2011 – In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate Therapeutics Read All » View HTML
Toggle Summary San Diego, CA and Ottawa, Canada (October 14, 2010) – Fate Therapeutics, Inc. has forged a collaboration and license agreement with BD (Becton, Dickinson and Company), a leading global medical technology company, through its BD Biosciences segment, for the joint development and worldwide Read All » View HTML
Toggle Summary San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today that the Company received Red Herring’s North America 100 award, a prestigious list honoring the year’s most promising private and innovative companies from the North American business region. Read All » View HTML
Toggle Summary San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of six respected research leaders to the Company’s Scientific Advisory Board (SAB). The new SAB members bring deep experience and expertise in systems biology, epigenetics, gene regulation, expression Read All » View HTML
Toggle Summary San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of Tom Novak, Ph.D., as vice president of research and drug discovery. Dr. Novak brings to Fate more than 15 years of experience working with large pharmaceutical companies, including Roche and Wyeth, to Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.